(Q26471022)

2 July 2019

review article

1 reference

title

Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history (English)

1 reference

2 July 2019

0 references

0 references

0 references

recurrent miscarriage

1 reference

Hengxi Chen

1

1 reference

2 July 2019

Jing Fu

series ordinal

2

1 reference

2 July 2019

Wei Huang

series ordinal

3

1 reference

2 July 2019

publication date

25 July 2016

1 reference

2 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

2 July 2019

volume

7

1 reference

2 July 2019

page(s)

CD008883

1 reference

2 July 2019

Quinagolide--a valuable treatment option for hyperprolactinaemia

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Reproductive toxicity of cabergoline in mice, rats, and rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205-502.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Clinical pharmacokinetics of cabergoline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Biosynthesis of Human Growth Hormone and Prolactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Risk factors in miscarriage: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Advances in the treatment of prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Prolactinomas, cabergoline, and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Progesterone for recurrent miscarriage: truth and deceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Hyperprolactinemia and prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Influence of past reproductive performance on risk of spontaneous abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Quinagolide in the management of prolactinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Recurrent miscarriage: current concepts in diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Drugs five years later. Bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Treatment of hyperprolactinemia: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Effects of nocturnal hyperprolactinemia on ovarian luteal function and galactorrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Accuracy of clinical diagnostic methods of threatened abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008883.PUB2

Endocrine abnormalities during the follicular phase in women with recurrent spontaneous abortion

21 January 2018

1 reference

12 December 2020

Vaginal bromocriptine administration in patients with hyperprolactinemia

1 reference

12 December 2020

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

1 reference

12 December 2020

Clinical management of prolactinomas

1 reference

12 December 2020

Vaginal bromocriptine--clinical and biochemical effects

1 reference

12 December 2020

Prolactin disorders in patients with habitual abortion

1 reference

12 December 2020

1 reference

12 December 2020

Recurrent miscarriage

1 reference

12 December 2020

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline

1 reference

12 December 2020

Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation

1 reference

12 December 2020

1 reference

12 December 2020

Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia

1 reference

12 December 2020

Bromocriptine in pregnancy: safety aspects

1 reference

12 December 2020

Factors influencing the secretion of human prolactin and growth hormone in menstrual and gestational women

1 reference

12 December 2020

Hyperprolactinaemia and luteal insufficiency

1 reference

12 December 2020

Transient hyperprolactinemia: a correctable cause of idiopathic female infertility

1 reference

12 December 2020

Surveillance of bromocriptine in pregnancy

1 reference

12 December 2020

[A study with diagnostic standard of occult hyperprolactinemia (OHP) and the effect of bromocriptine administration]

1 reference

12 December 2020

Occult hyperprolactinemia in infertile women

1 reference

12 December 2020

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

1 reference

12 December 2020

Outcome of pregnancies in women with treated or untreated hyperprolactinemia

1 reference

12 December 2020

The influence of latent hyperprolactinaemia on the levels of LH, FSH, E2 and T in the midfollicular phase of the cycle

1 reference

12 December 2020

Pregnancy after intravenous pulsatile gonadotropin-releasing hormone in a hyperprolactinaemic woman resistant to treatment with dopamine agonists

1 reference

12 December 2020

Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials

1 reference

12 December 2020

Hyperprolactinemic recurrent spontaneous pregnancy loss: a true clinical entity or a spurious finding?

1 reference

12 December 2020

10.1002/14651858.CD008883.PUB2

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6458049

1 reference

2 July 2019

PubMed publication ID

27455388

1 reference

2 July 2019